NPM1 and neoplasm: These engineered cells showed strong in vitro and in vivo activity against preclinical models of NPM1-mutated AML cells carrying NPM1-mutant/HLA-A2 complex but not against NPM1 wild-type/HLA-A2+ AML cells or HLA-A2 negative tumor cells [140].